Njofya5vq76vlfj5irdq aseda arrow

AsedaSciences®

1 Order Completed
West Lafayette, Indiana, US

About AsedaSciences®

AsedaSciences® was established in 2012 with the vision of becoming a leader in optimized drug discovery through innovative cellular analysis. We combine highly reproducible multiparametric live cell phenotypic screens with proprietary AI algorithms to predict risk of acute toxicity at the start of the Drug Discovery process (Hit-to-Lead). AsedaSciences uses...

Show more »

AsedaSciences® was established in 2012 with the vision of becoming a leader in optimized drug discovery through innovative cellular analysis. We combine highly reproducible multiparametric live cell phenotypic screens with proprietary AI algorithms to predict risk of acute toxicity at the start of the Drug Discovery process (Hit-to-Lead). AsedaSciences uses an approach similar to “facial recognition” by comparing biological ‘fingerprints’ of new compounds generated in our phenotypic screens to an extensive database of historical fingerprints (known toxins, withdrawn and marketed drugs). Based on similarity to fingerprints in the AsedaSciences database, our proprietary AI algorithms then transform the large biological data sets generated for each new compound into a single risk score, or Cell Health Index™, which is color coded to provide simple visual interpretation of risk severity. Similarity to fingerprints of known human toxins in the AsedaSciences database can be used by chemists as a strong predictor of future risk of failure in humans, allowing new compounds to be rapidly modified or removed from the pipeline years earlier, thus massively reducing cost and contributing to improvements in compound prioritization, animal welfare and patient safety.

Show less

Diversity Certificates

Small business

Our Services (3)


ic

Cell-Based Compound Screening

Price on request

AsedaSciences® provides multi-parametric, high content, high throughput phenotypic screening services to the bio-pharmaceutical industry. Our unique platform utilizes the inherent strengths of flow cytometry, automated processes and machine learning to deliver cost effective, high value toxicity predictions for small... Show more »

AsedaSciences® provides multi-parametric, high content, high throughput phenotypic screening services to the bio-pharmaceutical industry. Our unique platform utilizes the inherent strengths of flow cytometry, automated processes and machine learning to deliver cost effective, high value toxicity predictions for small molecules at the very start of the Drug Discovery process.

Our SYSTEMETRIC™ Cell Health Screen requires minimal compound (15-20 uL of 10 mM stock in DMSO) and simultaneously measures critical biological parameters indicative of cell health. We perform a standardized, 10 step dose response (100 uM down to 5 nM) that simultaneously measures Mitochondrial Membrane Potential, Reactive Oxygen Species (mitochondrially derived), Glutathione, Cytoplasmic and Nuclear Membrane Integrity, Cell Cycle and Morphology in each of approximately 10 thousand individual cells per concentration. This rich data set, which is unique for each compound, is then converted using a proprietary state-of-the-art algorithm into a high-dimensional biological fingerprint, which is then compared to a large and diverse training set of similar fingerprints from historical compounds, inclusive of known human toxins, withdrawn drugs and on-market therapeutics. Through multiple collaborations, we have demonstrated the ability to generate predictions with very high specificty and positive predictive value that are a tremendous tool for compound prioritization when integrated into the decision process at the start of Hit-to-Lead.

Our multiparametric approach generates an accurate risk assessment, termed the Cell Health Index™, which is color coded to provide chemists with an instant and easy visual intepretation of risk probability for acute toxicity in humans.  Our approach generates a risk profile for each compound, with the ability to discriminate between phenotypic changes down to small side chain differences in compound structure, providing a perfect tool for chemists to prioritize or modify compounds to decrease later stage failures that helps to improve pipeline quality, while providing significant financial gains by reducing late stage failures in either animals or humans.

Show less
Drug Discovery Toxicology Environmental Science Flow cytometry Phenotypic screening plate-based assay predictive toxicology Profiling toxicity testing Cytotoxicity Mitochondrial profiling Small molecules Show 12 more tags Show less

ic

Predictive Toxicology

Price on request

AsedaSciences has developed a cloud based, predictive platform for identification of toxicity risk at the start of Drug Discovery. Our approach transforms chemical structures into high value information. By combining a proprietary, biologically rich, phenotypic screening platform (flow cytometry) with machine learning... Show more »

AsedaSciences has developed a cloud based, predictive platform for identification of toxicity risk at the start of Drug Discovery. Our approach transforms chemical structures into high value information. By combining a proprietary, biologically rich, phenotypic screening platform (flow cytometry) with machine learning algorithms, we can provide the critical predictive insights missing from traditional in vitro toxicity screens.

Show less

ic

Drug Discovery

Price on request

The AsedaSciences platform has demonstrted the ability to discriminate changes in acute cellular stress down to the single side chain level on a compound scaffold. Such fidelity in the visualization of phenotypic changes resulting from small differences in compound structure has enabled a dual purpose approach to the use of the... Show more »

The AsedaSciences platform has demonstrted the ability to discriminate changes in acute cellular stress down to the single side chain level on a compound scaffold. Such fidelity in the visualization of phenotypic changes resulting from small differences in compound structure has enabled a dual purpose approach to the use of the platform - for both risk assessment and drug discovery. We are interested in accessing historical compound libraries from small molecule projects that were discontinued for reasons associated with toxicity. Please contact us for further information.

Show less

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
BC

Brad Calvin

President and co-founder

FileType/PDF Created with Sketch. AsedaSciences Systemetric™ Cell Health Screen.pdf

Click to Download

AsedaSciences® has not received any reviews.

AsedaSciences® has not received any endorsements.